Pancreatic Cancer Research

ResearcherChinese PLA General HospitalActive in the last 2 years

Renyi Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5101-5259, 0000-0003-1654-1285; OpenAlex author ID A5102755218, A5102792018, A5109509147. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 2, last author 31)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
126
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers · 2018: 7 papers · 2019: 3 papers, 1 trial · 2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 6 papers · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 44

  1. USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibiting glucose uptake. Last author DOI 10.1016/j.canlet.2026.218299↗
  2. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Last author DOI 10.1038/s41418-026-01665-1↗
  3. The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-025-08052-7↗
  4. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08225-y↗
  5. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  6. Post-Translational Modifications: Key "Regulators" of Pancreatic Cancer Malignant Phenotype-Advances in Mechanisms and Targeted Therapies. First author DOI 10.3390/biomedicines13123013↗
  7. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Last author DOI 10.1001/jamasurg.2023.5210↗
  8. A comparative study of the "superior mesenteric artery first" approach versus the conventional approach in short-term and long-term outcomes in patients with p… Last author DOI 10.1007/s00464-023-10470-7↗
  9. Minimally invasive versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: Individual patient data meta-analysis of randomized trials. Last author DOI 10.1016/j.ejso.2023.03.227↗
  10. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41418-022-01040-w↗
  11. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  12. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Last author DOI 10.3389/fimmu.2023.1332626↗
  13. OPA Interacting Protein 5 Antisense RNA 1 Expedites Cell Migration and Invasion Through FOXM1/ Wnt/β-Catenin Pathway in Pancreatic Cancer. Last author DOI 10.1007/s10620-021-06919-1↗
  14. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Last author DOI 10.1016/j.ebiom.2022.104352↗
  15. How can we better predict the prognosis of patients with pancreatic cancer undergoing surgery using an immune-nutritional scoring system? Last author DOI 10.1016/j.surg.2021.12.009↗
  16. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Last author DOI 10.1186/s13046-022-02491-2↗
  17. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.765216↗
  18. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. Last author DOI 10.3390/genes12111701↗
  19. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Last author DOI 10.7150/ijbs.49514↗
  20. MiR-146b-3p regulates proliferation of pancreatic cancer cells with stem cell-like properties by targeting MAP3K10. Last author DOI 10.7150/jca.48418↗
  21. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Last author DOI 10.1186/s12943-020-01249-8↗
  22. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Co-author DOI 10.1016/j.tiv.2018.10.019↗
  23. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Last author DOI 10.1038/s41419-019-2123-y↗
  24. PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. Last author DOI 10.3389/fphar.2019.00968↗
  25. Loss of Linc01060 induces pancreatic cancer progression through vinculin-mediated focal adhesion turnover. Last author DOI 10.1016/j.canlet.2018.06.015↗
  26. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Last author DOI 10.1016/j.taap.2018.08.003↗
  27. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Last author DOI 10.1038/s41598-018-22493-5↗
  28. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. Last author DOI 10.1186/s12885-018-4948-7↗
  29. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Last author DOI 10.18632/oncotarget.22976↗
  30. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.24443↗
  31. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Last author DOI 10.7150/ijbs.26776↗
  32. Which Is the Best Surgical Approach for the Pancreatic Cancer? A Classification of Pancreatic Cancer to Guide Operative Decisions Is Needed. Co-author DOI 10.1097/sla.0000000000001271↗
  33. Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin. Last author DOI 10.3390/ijms18020370↗
  34. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Last author DOI 10.1007/s10238-015-0365-2↗
  35. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Last author DOI 10.1016/s1499-3872(15)60413-1↗
  36. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-1144↗
  37. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  38. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in huma… Last author DOI 10.1016/j.canlet.2014.11.026↗
  39. The NOTCH ligand JAGGED2 promotes pancreatic cancer metastasis independent of NOTCH signaling activation. Co-author DOI 10.1158/1535-7163.mct-14-0501↗
  40. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  41. [A new classification of pancreatic cancer to guide operative decisions and the comparison with the TNM stage]. Co-author PMID 26359069↗
  42. KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0025-5↗
  43. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Last author DOI 10.1158/1541-7786.mcr-12-0632↗
  44. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. First author DOI 10.1007/s10620-010-1340-0↗

Trials 1

  1. Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma Principal investigator NCT03785743↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Wang · 26 shared papers, 2013–2026 · strength 3.30
  2. Shutao Pan · 14 shared papers, 2018–2026 · strength 1.78
  3. Xingjun Guo · 19 shared papers, 2013–2023 · strength 1.73
  4. Ruizhi He · 15 shared papers, 2016–2022 · strength 1.29
  5. Chunle Zhao · 10 shared papers, 2018–2026 · strength 1.21
  6. Yongkang Shi · 5 shared papers, 2022–2026 · strength 1.21
  7. Jun Gong · 6 shared papers, 2020–2026 · strength 1.08
  8. Zhenxiong Zhang · 6 shared papers, 2022–2026 · strength 1.07
  9. Taoyuan Yin · 6 shared papers, 2019–2026 · strength 0.93
  10. Min Zhou · 4 shared papers, 2023–2026 · strength 0.86
  11. Xiuhui Shi · 9 shared papers, 2018–2022 · strength 0.83
  12. Li Xu · 7 shared papers, 2013–2022 · strength 0.76
  13. Yan Zhao · 9 shared papers, 2016–2022 · strength 0.65
  14. Chengjian Shi · 8 shared papers, 2011–2022 · strength 0.58
  15. Guangbing Xiong · 3 shared papers, 2021–2025 · strength 0.57
  16. Min Zhou · 6 shared papers, 2018–2021 · strength 0.55
  17. Min Zhou · 5 shared papers, 2018–2022 · strength 0.54
  18. Yu Bai · 2 shared papers, 2026 · strength 0.49
  19. Xu Li · 6 shared papers, 2015–2022 · strength 0.47
  20. Yiming Li · 1 shared paper, 2025 · strength 0.42
  21. Yuhui Liu · 4 shared papers, 2019–2022 · strength 0.42
  22. Xianjun Yu · 4 shared papers, 2015–2025 · strength 0.38
  23. Jianxin Jiang · 7 shared papers, 2013–2020 · strength 0.38
  24. Chen Liu · 3 shared papers, 2015–2025 · strength 0.34
  25. Shuo Yu · 3 shared papers, 2018–2021 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.